Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
| dc.authorid | 0000-0002-0561-2749 | |
| dc.authorid | 0000-0002-0121-9683 | |
| dc.authorid | 0000-0002-5364-4366 | |
| dc.authorid | 0000-0003-2054-1691 | |
| dc.authorid | 0000-0002-7555-6201 | |
| dc.authorid | 0000-0002-3073-6890 | |
| dc.authorid | 0000-0002-8636-7174 | |
| dc.contributor.author | Yusuf, Salim | |
| dc.contributor.author | Joseph, Philip | |
| dc.contributor.author | Rangarajan, Sumathy | |
| dc.contributor.author | Islam, Shofiqul | |
| dc.contributor.author | Mente, Andrew | |
| dc.contributor.author | Hystad, Perry | |
| dc.contributor.author | Brauer, Michael | |
| dc.date.accessioned | 2025-05-10T19:44:03Z | |
| dc.date.issued | 2020 | |
| dc.department | İstanbul Medeniyet Üniversitesi | |
| dc.description.abstract | Background Global estimates of the effect of common modifiable risk factors on cardiovascular disease and mortality are largely based on data from separate studies, using different methodologies. The Prospective Urban Rural Epidemiology (PURE) study overcomes these limitations by using similar methods to prospectively measure the effect of modifiable risk factors on cardiovascular disease and mortality across 21 countries (spanning five continents) grouped by different economic levels. Methods In this multinational, prospective cohort study, we examined associations for 14 potentially modifiable risk factors with mortality and cardiovascular disease in 155 722 participants without a prior history of cardiovascular disease from 21 high-income, middle-income, or low-income countries (HICs, MICs, or LICs). The primary outcomes for this paper were composites of cardiovascular disease events (defined as cardiovascular death, myocardial infarction, stroke, and heart failure) and mortality. We describe the prevalence, hazard ratios (HRs), and population-attributable fractions (PAFs) for cardiovascular disease and mortality associated with a cluster of behavioural factors (ie, tobacco use, alcohol, diet, physical activity, and sodium intake), metabolic factors (ie, lipids, blood pressure, diabetes, obesity), socioeconomic and psychosocial factors (ie, education, symptoms of depression), grip strength, and household and ambient pollution. Associations between risk factors and the outcomes were established using multivariable Cox frailty models and using PAFs for the entire cohort, and also by countries grouped by income level. Associations are presented as HRs and PAFs with 95% CIs. Findings Between Jan 6, 2005, and Dec 4, 2016, 155 722 participants were enrolled and followed up for measurement of risk factors. 17 249 (11.1%) participants were from HICs, 102 680 (65.9%) were from MICs, and 35 793 (23.0%) from LICs. Approximately 70% of cardiovascular disease cases and deaths in the overall study population were attributed to modifiable risk factors. Metabolic factors were the predominant risk factors for cardiovascular disease (41.2% of the PAF), with hypertension being the largest (22.3% of the PAF). As a cluster, behavioural risk factors contributed most to deaths (26.3% of the PAF), although the single largest risk factor was a low education level (12.5% of the PAF). Ambient air pollution was associated with 13.9% of the PAF for cardiovascular disease, although different statistical methods were used for this analysis. In MICs and LICs, household air pollution, poor diet, low education, and low grip strength had stronger effects on cardiovascular disease or mortality than in HICs. Interpretation Most cardiovascular disease cases and deaths can be attributed to a small number of common, modifiable risk factors. While some factors have extensive global effects (eg, hypertension and education), others (eg, household air pollution and poor diet) vary by a country's economic level. Health policies should focus on risk factors that have the greatest effects on averting cardiovascular disease and death globally, with additional emphasis on risk factors of greatest importance in specific groups of countries. Copyright (C) 2019 Elsevier Ltd. All rights reserved. | |
| dc.description.sponsorship | Population Health Research Institute; Hamilton Health Sciences Research Institute; Canadian Institutes of Health Research (through the Strategy for Patient-Oriented Research via the Ontario SPOR Support Unit); Heart and Stroke Foundation (ON, Canada); Ontario Ministry of Health and Long-Term Care; Canadian Institutes for Health Research [136893]; Office of the Director, National Institutes of Health [DP500019850] | |
| dc.description.sponsorship | We thank Patrick Sheridan for additional statistical support and Matthew McQueen for supervising and standardising the laboratory analyses. The PURE study is funded by the Population Health Research Institute, Hamilton Health Sciences Research Institute, the Canadian Institutes of Health Research (including through the Strategy for Patient-Oriented Research via the Ontario SPOR Support Unit), the Heart and Stroke Foundation (ON, Canada), the Ontario Ministry of Health and Long-Term Care. The PURE-AIR study is funded by the Canadian Institutes for Health Research (grant 136893) and by the Office of the Director, National Institutes of Health (award DP500019850). It is also funded by unrestricted grants from several pharmaceutical companies, with major contributions from AstraZeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier Laboratories, and GlaxoSmithKline, and additional contributions from Novartis, King Pharma, and from several national and local organisations in participating countries. Further details on the funding and participating countries and institutions, and on collaborating staff, are shown in the appendix (pp 24-31). | |
| dc.identifier.doi | 10.1016/S0140-6736(19)32008-2 | |
| dc.identifier.endpage | 808 | |
| dc.identifier.issn | 0140-6736 | |
| dc.identifier.issn | 1474-547X | |
| dc.identifier.issue | 10226 | |
| dc.identifier.pmid | 31492503 | |
| dc.identifier.scopus | 2-s2.0-85080843337 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.startpage | 795 | |
| dc.identifier.uri | https://doi.org/10.1016/S0140-6736(19)32008-2 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14730/10792 | |
| dc.identifier.volume | 395 | |
| dc.identifier.wos | WOS:000519536900036 | |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Elsevier Science Inc | |
| dc.relation.ispartof | Lancet | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WOS_20250302 | |
| dc.subject | Urinary Sodium | |
| dc.subject | Myocardial-Infarction | |
| dc.subject | Potassium Excretion | |
| dc.subject | Blood-Pressure | |
| dc.title | Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study | |
| dc.type | Article |
Dosyalar
Orijinal paket
1 - 1 / 1










